ZIOP
Price:
$0.8657
Market Cap:
$208.12M
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chim...[Read more]
Industry
Biotechnology
IPO Date
2004-08-20
Stock Exchange
NASDAQ
Ticker
ZIOP
According to ZIOPHARM Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.07. This represents a change of -67.42% compared to the average of -6.34 of the last 4 quarters.
The mean historical PE Ratio of ZIOPHARM Oncology, Inc. over the last ten years is -7.24. The current -2.07 PE Ratio has changed 2.76% with respect to the historical average. Over the past ten years (40 quarters), ZIOP's PE Ratio was at its highest in in the June 2016 quarter at -1.36. The PE Ratio was at its lowest in in the December 2015 quarter at -28.47.
Average
-7.24
Median
-6.57
Minimum
-16.13
Maximum
-3.40
Discovering the peaks and valleys of ZIOPHARM Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 147.29%
Maximum Annual PE Ratio = -3.40
Minimum Annual Increase = -51.52%
Minimum Annual PE Ratio = -16.13
Year | PE Ratio | Change |
---|---|---|
2020 | -6.61 | -1.85% |
2019 | -6.73 | 33.02% |
2018 | -5.06 | -51.52% |
2017 | -10.44 | 147.29% |
2016 | -4.22 | -51.37% |
2015 | -8.68 | -46.21% |
2014 | -16.13 | 147.01% |
2013 | -6.53 | 92.16% |
2012 | -3.40 | -25.52% |
2011 | -4.56 | -30.45% |
The current PE Ratio of ZIOPHARM Oncology, Inc. (ZIOP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.13
5-year avg
-6.61
10-year avg
-7.24
ZIOPHARM Oncology, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ZIOPHARM Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ZIOPHARM Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ZIOPHARM Oncology, Inc.'s PE Ratio?
How is the PE Ratio calculated for ZIOPHARM Oncology, Inc. (ZIOP)?
What is the highest PE Ratio for ZIOPHARM Oncology, Inc. (ZIOP)?
What is the 3-year average PE Ratio for ZIOPHARM Oncology, Inc. (ZIOP)?
What is the 5-year average PE Ratio for ZIOPHARM Oncology, Inc. (ZIOP)?
How does the current PE Ratio for ZIOPHARM Oncology, Inc. (ZIOP) compare to its historical average?